Gossamer Bio, Inc. (GOSS)
Market: NASD |
Currency: USD
Address: 3013 Science Park Road
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
Show more
📈 Gossamer Bio, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$8.03
-
Upside/Downside from Analyst Target:
372.43%
-
Broker Call:
16
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
50-100%
-
Net Income Growth Range (1Y):
50-100%
-
Revenue Growth Range (1Y):
-
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Gossamer Bio, Inc.
| Date | Reported EPS |
|---|
| 2025-08-11 (estimated upcoming) | - |
| 2025-05-15 | -0.16 |
| 2025-03-13 | -0.15 |
| 2024-11-07 | -0.14 |
| 2024-08-12 | 0.22 |
| 2024-05-07 | -0.19 |
| 2024-03-05 | -0.21 |
| 2023-11-09 | -0.21 |
| 2023-08-08 | -0.45 |
| 2023-05-09 | -0.52 |
| 2023-03-17 | -0.59 |
| 2022-11-03 | -0.65 |
| 2022-08-09 | -0.74 |
| 2022-05-10 | -0.76 |
| 2022-03-03 | -0.74 |
| 2021-11-08 | -0.8 |
| 2021-08-09 | -0.8 |
| 2021-05-06 | -0.78 |
| 2021-02-25 | -0.88 |
| 2020-11-10 | -0.8 |
| 2020-08-11 | -1 |
| 2020-05-12 | -0.87 |
| 2020-03-24 | -0.89 |
| 2019-11-12 | -0.8 |
| 2019-08-08 | -0.74 |
📰 Related News & Research
No related articles found for "gossamer bio".
